Questcor's stock leapt nearly 40% during trading yesterday as investors welcomed its $135m-plus purchase of Novartis' rival immune drug Synacthen. The US speciality pharma said it has bought rights to develop Synacthen (tetracosactide) …
Mallinckrodt's stock closed down 1 percent on Friday ... when the drug was …
CNBC14d
Irish pharmaceutical giant Mallinckrodt Pharmaceuticals said it will pay $5.6 billion ... $30 in cash and 0.897 of a share of Mallinckrodt stock for each share of Questcor common stock they own. Based on the closing price of Mallinckrodt and …
Publicis Groupe (PUBGY): Shares are now Neutral from Overweigh at HSBC Securities. Questcor Pharmaceuticals (QCOR): The stock is downgraded to Market Perform from Outperform at Leerink.
Questcor to Acquire Nascobal, a Specialty Drug Used by Patients with Multiple Sclerosis and Inflammatory Bowel …
After this news, Questcor’s stock plummeted 48 percent to close at $26.35 per share on Sept. 19, 2012, the suit states. Then Questcor announced the U.S. government had launched an investigation into the company’s promotional …
Valeant will pay $44 a share for Medicis, a 39% premium to the stock’s Friday closing price. Medicis shares surged 38% to $43.47 premarket; Valeant shares were also higher, trading up 9.8% to $56.29. Questcor Pharmaceuticals Inc. …
Shares of Questcor originally leaped over the 27% premium Mallinckrodt is paying, but the stock has pulled back some. Questcor is something of a one-trick pony. But it is a big trick. The company’s H.P. Acthar injectable gel has been …
Questcor's shares were trading at $77 on the Nasdaq on Monday afternoon. Mallinckrodt was down 6 percent at $58.50 on the New York Stock Exchange. The deal - the latest in a series of acquisitions structured to take advantage of Ireland's …
It's better news for Agios Pharmaceuticals (AGIO). The stock ended up over 25% after the company reported promising results in the first clinical trial of its leukemia drug. Questcor Pharmaceutical (QCOR)was one of the top trending …